Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the safety and efficacy of insulin analogs and human insulins both during acute intravenous treatment and during the transition to subcutaneous insulin in patients with diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS: In a controlled multicenter and open-label trial, we randomly assigned patients with DKA to receive intravenous treatment with regular or glulisine insulin until resolution of DKA. After resolution of ketoacidosis, patients treated with intravenous regular insulin were transitioned to subcutaneous NPH and regular insulin twice daily (n = 34). Patients treated with intravenous glulisine insulin were transitioned to subcutaneous glargine once daily and glulisine before meals (n = 34). RESULTS: There were no differences in the mean duration of treatment or in the amount of insulin infusion until resolution of DKA between intravenous treatment with regular and glulisine insulin. After transition to subcutaneous insulin, there were no differences in mean daily blood glucose levels, but patients treated with NPH and regular insulin had a higher rate of hypoglycemia (blood glucose <70 mg/dl). Fourteen patients (41%) treated with NPH and regular insulin had 26 episodes of hypoglycemia and 5 patients (15%) in the glargine and glulisine group had 8 episodes of hypoglycemia (P = 0.03). CONCLUSIONS: Regular and glulisine insulin are equally effective during the acute treatment of DKA. A transition to subcutaneous glargine and glulisine after resolution of DKA resulted in similar glycemic control but in a lower rate of hypoglycemia than with NPH and regular insulin. Thus, a basal bolus regimen with glargine and glulisine is safer and should be preferred over NPH and regular insulin after the resolution of DKA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Automated, computerized, IV insulin protocols, including commercially available or institutional-based protocols, have improved glycemic control, with good acceptance by nursing personnel.1294–1307”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1301]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266 · cited 1×
“In recent years, the use of long-acting basal and rapid-acting insulin analogs have been recommended as a more physiologic approach than NPH and regular insulin for glucose control in the hospital;(12; 13) however, no previous studies have evaluated the safety and efficacy of insulin analogs in the management of patie…”
BackgroundManagement of Hyperglycemic Crises in Patients With Diabetes
Kitabchi, A. E., Umpierrez, G. E., Murphy, M. B., Barrett, E. J., Kreisberg, R. A., Malone, J. I., & Wall, B. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.131 · Cited by 710 · cited 5×
“and substantial spending related to direct and indirect costs (2).”
BackgroundInfluentialSelf-citationSevere hypoglycemia in critically ill patients: risk factors and outcomes
Krinsley, J. S., & Grover, A. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000282073.98414.4b · Cited by 671 · cited 1×
“Minimizing the rate of hypoglycemia events is of major importance in hospitalized patients because it may represent an independent risk factor of poor clinical outcome (24).”
BackgroundUmpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., & Mejia, R. (2007) · Diabetes Care · doi:10.2337/dc07-0295 · Cited by 671
Self-citationHyperglycemic Crises in Adult Patients With Diabetes
Kitabchi, A. E., Umpierrez, G. E., Murphy, M. B., & Kreisberg, R. A. (2006) · Diabetes Care · doi:10.2337/dc06-9916 · Cited by 512
Self-citationManagement of Hyperglycemia in the Hospital Setting
Inzucchi, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp060094 · Cited by 391
Owens, D. R., Zinman, B., & Bolli, G. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05842-1 · Cited by 373 · cited 1×
“Glulisine has a faster onset of action and a shorter duration of action after subcutaneous injection compared with regular insulin (21,22).”
BackgroundMonomeric Insulins and Their Experimental and Clinical Implications
Brange, J., Owens, D. R., Kang, S., & Vølund, A. (1990) · Diabetes Care · doi:10.2337/diacare.13.9.923 · Cited by 369 · cited 1×
“Glulisine has a faster onset of action and a shorter duration of action after subcutaneous injection compared with regular insulin (21,22).”
BackgroundHyperglycemic Crises in Urban Blacks
Umpierrez, G. E. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.6.669 · Cited by 295 · cited 5×
“The rate of hypoglycemic events in this study is similar to the rate reported previously with the use of NPH and regular insulin after discontinuation of intravenous therapy (3,9).”
BackgroundMethodResultInfluentialSelf-citationVariability of Insulin Absorption and Insulin Action
Heinemann, L. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/152091502320798312 · Cited by 267 · cited 2×
“in absorption (11) partially explains the”
Background
Cited by
Items 101–123 of 123
Zelinska, N. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-4-39 · Cited by 1
Hypoglycaemia incidence with a simple, low-dose insulin protocol for adult diabetic ketoacidosis
Patel, N., Cusumano, M. C., & Lorenson, J. (2022) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riac046 · Cited by 1
Clinical Management of Diabetic Ketoacidosis in Pregnancy: A Review of Current Literature
Niyondiko, N. (2024) · OALib · doi:10.4236/oalib.1112246 · Cited by 1
Insulina aspart en el tratamiento de la hiperglucemia hospitalaria
Pérez, A., & Miñambres, I. (2012) · Avances en Diabetología · doi:10.1016/s1134-3230(12)70023-6 · Cited by 1
Comparing conventional and analogue insulin in hospitalised patients.
Menaka, R., Narendra, B., Sandeep, J. A., & Bhattacharyya, A. (2014) · PubMed
Нюанси інсулінотерапії при лікуванні діабетичного кетоацидозу
Nizhynska-Аstapenko, Z. P., & Vlasenkо, М. V. (2017) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.13.5.2017.110025
“3 unit/kg/h in case of subcutaneous administration [5, 8, 11].”
BackgroundHuman insulin — is there still a place for it in everyday practice?
Nabrdalik, K., Kwiendacz, H., & Gumprecht, J. (2018) · Clinical Diabetology · doi:10.5603/dk.2018.0014
“Należy jednak podkreślić, że w odniesieniu do okresu po zakończeniu ostrej fazy dekompensacji cukrzycy zastosowanie insulin analogowych wiązało się z mniejszą częstością epizodów hipoglikemii [18].”
Insuliny ludzkie — czy współcześnie jest jeszcze dla nich miejsce w codziennej praktyce?
Nabrdalik, K., Kwiendacz, H., & Gumprecht, J. (2018) · Via Medica Journals
Leurcharusmee, P., Kositratna, G., Tran, D. Q. H., & Schricker, T. (2017) · Asian Biomedicine · doi:10.1515/abm-2018-0014
Coventional Insulin versus Insulin Analogs
Gomber, A., & Gomber, A. (2019) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/jmgims.jmgims_5_19 · Cited by 1
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1015
Diabetisches Koma und perioperative Diabetestherapie
Berndt, M., Klose, S., & Lehnert, H. (2015) · Springer eBooks · doi:10.1007/978-3-642-54675-4_78-1
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
Lam, D. W.-H., & Feng, Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_18-4
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
Lam, D. W.-H., Feng, Y., & Fleckman, A. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_18-2 · Cited by 1
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
Lam, D. W.-H., & Feng, Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_18-3
(2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0738-6.00012-7
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
Lam, D. W.-H., & Feng, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_18 · Cited by 1
Pharmaceutical Biotechnology: The Arrival of Recombinant Proteins
(2015) · CRC Press eBooks · doi:10.1201/b18392-3
Gore, S. B. (2016) · Springer eBooks · doi:10.1007/978-81-322-2710-6_36
Treatment Considerations and Pharmacist Collaborative Care in Diabetic Ketoacidosis Management
Algarni, A. S. (2022) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x221128643
The African Face of Childhood Diabetes
Majaliwa, E., Ameyawak, E., Bulemela, J., & Abdalla, A. T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108723
Alexanian, S. M., Cheney, M. C., Spartano, N. L., Bello-Ramos, J. C., Reddy, N., Malik, A., Murati, J., Wolpert, H. A., & Steenkamp, D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.015
Development of an Advanced Drug Delivery System for Protein- and Peptide-Based Therapeutics
Lai, W. F., Kee, P. E., Ming, L. C., Chew, Y.-L., Lee, S.-K., Bostanudin, M. F., Uddin, A. B. M. H., & Liew, K. B. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128394343250910234044
Metadata
- Authors
- Umpierrez, G. E., Jones, S., Smiley, D., Mulligan, P., Keyler, T., Temponi, A., Semakula, C., Umpierrez, D., Peng, L., Cerón, M., & Robalino, G.
- Affiliations
- Emory University (US)
- University of Minnesota (US)
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia;
- Corresponding author
- Umpierrez, Guillermo E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-04-14
- Volume
- 32
- Issue
- 7
- Pages
- 1164-1169
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2699711
- OpenAlex
- W2123006117
- Cited by
- 120
- References
- 25
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 9 · 2021: 4 · 2020: 12 · 2019: 4 · 2018: 11 · 2017: 9 · 2016: 9 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 12
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (7-03-CR-35)
- Sanofi
- National Institutes of Health (UL1TR000454)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK074556)
- National Center for Research Resources (M01-RR00039, M01RR000039)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- diabetic ketoacidosis, insulin analogues, regular insulin, NPH insulin, insulin glargine, multiple daily insulin injections, hypoglycemia, glycemic control, intravenous insulin therapy
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin, Isophane, Male, Middle Aged, Patient Compliance, Recombinant Proteins, Diabetic Ketoacidosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.